<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31801298</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>23</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6055</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms20236055</ELocationID><Abstract><AbstractText>MicroRNAs are post-transcriptional regulators of gene expression, crucial for neuronal differentiation, survival, and activity. Age-related dysregulation of microRNA biogenesis increases neuronal vulnerability to cellular stress and may contribute to the development and progression of neurodegenerative diseases. All major neurodegenerative disorders are also associated with oxidative stress, which is widely recognized as a potential target for protective therapies. Albeit often considered separately, microRNA networks and oxidative stress are inextricably entwined in neurodegenerative processes. Oxidative stress affects expression levels of multiple microRNAs and, conversely, microRNAs regulate many genes involved in an oxidative stress response. Both oxidative stress and microRNA regulatory networks also influence other processes linked to neurodegeneration, such as mitochondrial dysfunction, deregulation of proteostasis, and increased neuroinflammation, which ultimately lead to neuronal death. Modulating the levels of a relatively small number of microRNAs may therefore alleviate pathological oxidative damage and have neuroprotective activity. Here, we review the role of individual microRNAs in oxidative stress and related pathways in four neurodegenerative conditions: Alzheimer's (AD), Parkinson's (PD), Huntington's (HD) disease, and amyotrophic lateral sclerosis (ALS). We also discuss the problems associated with the use of oversimplified cellular models and highlight perspectives of studying microRNA regulation and oxidative stress in human stem cell-derived neurons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Konovalova</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0534-8028</Identifier><AffiliationInfo><Affiliation>Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerasymchuk</LastName><ForeName>Dmytro</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Biology and Genetics, NASU, Kyiv 03143, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parkkinen</LastName><ForeName>Ilmari</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chmielarz</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Brain Biochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domanskyi</LastName><ForeName>Andrii</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4755-5981</Identifier><AffiliationInfo><Affiliation>Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>293392, 319195</GrantID><Agency>Academy of Finland</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Huntington&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">ROS</Keyword><Keyword MajorTopicYN="N">microRNA</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">translation regulation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31801298</ArticleId><ArticleId IdType="pmc">PMC6929013</ArticleId><ArticleId IdType="doi">10.3390/ijms20236055</ArticleId><ArticleId IdType="pii">ijms20236055</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Erkkinen M.G., Kim M.O., Geschwind M.D. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect. Biol. 2018;10 doi: 10.1101/cshperspect.a033118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a033118</ArticleId><ArticleId IdType="pmc">PMC5880171</ArticleId><ArticleId IdType="pubmed">28716886</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators G.B.D.N. Global, regional, and national burden of neurological disorders, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459&#x2013;480. doi: 10.1016/S1474-4422(18)30499-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30499-X</ArticleId><ArticleId IdType="pmc">PMC6459001</ArticleId><ArticleId IdType="pubmed">30879893</ArticleId></ArticleIdList></Reference><Reference><Citation>Pringsheim T., Jette N., Frolkis A., Steeves T.D. The prevalence of Parkinson&#x2019;s disease: A systematic review and meta-analysis. Mov. Disord. 2014;29:1583&#x2013;1590. doi: 10.1002/mds.25945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25945</ArticleId><ArticleId IdType="pubmed">24976103</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787&#x2013;795. doi: 10.1038/nature05292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05292</ArticleId><ArticleId IdType="pubmed">17051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Blesa J., Trigo-Damas I., Quiroga-Varela A., Jackson-Lewis V.R. Oxidative stress and Parkinson&#x2019;s disease. Front. Neuroanat. 2015;9:91. doi: 10.3389/fnana.2015.00091.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2015.00091</ArticleId><ArticleId IdType="pmc">PMC4495335</ArticleId><ArticleId IdType="pubmed">26217195</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonnies E., Trushina E. Oxidative Stress, Synaptic Dysfunction, and Alzheimer&#x2019;s Disease. J. Alzheimers Dis. 2017;57:1105&#x2013;1121. doi: 10.3233/JAD-161088.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-161088</ArticleId><ArticleId IdType="pmc">PMC5409043</ArticleId><ArticleId IdType="pubmed">28059794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Ratan R.R. Oxidative stress and Huntington&#x2019;s disease: The good, the bad, and the ugly. J. Huntingtons Dis. 2016;5:217&#x2013;237. doi: 10.3233/JHD-160205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JHD-160205</ArticleId><ArticleId IdType="pmc">PMC5310831</ArticleId><ArticleId IdType="pubmed">27662334</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedzielska E., Smaga I., Gawlik M., Moniczewski A., Stankowicz P., Pera J., Filip M. Oxidative stress in neurodegenerative diseases. Mol. Neurobiol. 2016;53:4094&#x2013;4125. doi: 10.1007/s12035-015-9337-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9337-5</ArticleId><ArticleId IdType="pmc">PMC4937091</ArticleId><ArticleId IdType="pubmed">26198567</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbulla L.F., Song P., Mazzulli J.R., Zampese E., Wong Y.C., Jeon S., Santos D.P., Blanz J., Obermaier C.D., Strojny C., et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson&#x2019;s disease. Science. 2017;357:1255&#x2013;1261. doi: 10.1126/science.aam9080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aam9080</ArticleId><ArticleId IdType="pmc">PMC6021018</ArticleId><ArticleId IdType="pubmed">28882997</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobley J.N., Fiorello M.L., Bailey D.M. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol. 2018;15:490&#x2013;503. doi: 10.1016/j.redox.2018.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2018.01.008</ArticleId><ArticleId IdType="pmc">PMC5881419</ArticleId><ArticleId IdType="pubmed">29413961</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacelli C., Giguere N., Bourque M.J., Levesque M., Slack R.S., Trudeau L.E. Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr. Biol. 2015;25:2349&#x2013;2360. doi: 10.1016/j.cub.2015.07.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2015.07.050</ArticleId><ArticleId IdType="pubmed">26320949</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Zhou T., Ziegler A.C., Dimitrion P., Zuo L. Oxidative stress in neurodegenerative diseases: From molecular mechanisms to clinical applications. Oxid. Med. Cell Longev. 2017;2017:2525967. doi: 10.1155/2017/2525967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/2525967</ArticleId><ArticleId IdType="pmc">PMC5529664</ArticleId><ArticleId IdType="pubmed">28785371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G.H., Kim J.E., Rhie S.J., Yoon S. The role of oxidative stress in neurodegenerative diseases. Exp. Neurobiol. 2015;24:325&#x2013;340. doi: 10.5607/en.2015.24.4.325.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2015.24.4.325</ArticleId><ArticleId IdType="pmc">PMC4688332</ArticleId><ArticleId IdType="pubmed">26713080</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy M.P. Antioxidants as therapies: Can we improve on nature? Free Radic. Biol. Med. 2014;66:20&#x2013;23. doi: 10.1016/j.freeradbiomed.2013.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.04.010</ArticleId><ArticleId IdType="pubmed">23603661</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasconcelos A.R., Dos Santos N.B., Scavone C., Munhoz C.D. Nrf2/ARE pathway modulation by dietary energy regulation in neurological disorders. Front. Pharmacol. 2019;10:33. doi: 10.3389/fphar.2019.00033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00033</ArticleId><ArticleId IdType="pmc">PMC6369171</ArticleId><ArticleId IdType="pubmed">30778297</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281&#x2013;297. doi: 10.1016/S0092-8674(04)00045-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(04)00045-5</ArticleId><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel D.P. Metazoan MicroRNAs. Cell. 2018;173:20&#x2013;51. doi: 10.1016/j.cell.2018.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.006</ArticleId><ArticleId IdType="pmc">PMC6091663</ArticleId><ArticleId IdType="pubmed">29570994</ArticleId></ArticleIdList></Reference><Reference><Citation>Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010;11:597&#x2013;610. doi: 10.1038/nrg2843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg2843</ArticleId><ArticleId IdType="pubmed">20661255</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmiedel J.M., Klemm S.L., Zheng Y., Sahay A., Bluthgen N., Marks D.S., van Oudenaarden A. Gene expression. MicroRNA control of protein expression noise. Science. 2015;348:128&#x2013;132. doi: 10.1126/science.aaa1738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa1738</ArticleId><ArticleId IdType="pubmed">25838385</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajman M., Schratt G. MicroRNAs in neural development: From master regulators to fine-tuners. Development. 2017;144:2310&#x2013;2322. doi: 10.1242/dev.144337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.144337</ArticleId><ArticleId IdType="pubmed">28676566</ArticleId></ArticleIdList></Reference><Reference><Citation>Im H.I., Kenny P.J. MicroRNAs in neuronal function and dysfunction. Trends Neurosci. 2012;35:325&#x2013;334. doi: 10.1016/j.tins.2012.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2012.01.004</ArticleId><ArticleId IdType="pmc">PMC3565236</ArticleId><ArticleId IdType="pubmed">22436491</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein E., Kim S.Y., Carmell M.A., Murchison E.P., Alcorn H., Li M.Z., Mills A.A., Elledge S.J., Anderson K.V., Hannon G.J. Dicer is essential for mouse development. Nat. Genet. 2003;35:215&#x2013;217. doi: 10.1038/ng1253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1253</ArticleId><ArticleId IdType="pubmed">14528307</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita S., Horii T., Kimura M., Goto Y., Ochiya T., Hatada I. One Argonaute family member, Eif2c2 (Ago2), is essential for development and appears not to be involved in DNA methylation. Genomics. 2007;89:687&#x2013;696. doi: 10.1016/j.ygeno.2007.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2007.01.004</ArticleId><ArticleId IdType="pubmed">17418524</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawase-Koga Y., Otaegi G., Sun T. Different timings of Dicer deletion affect neurogenesis and gliogenesis in the developing mouse central nervous system. Dev. Dyn. 2009;238:2800&#x2013;2812. doi: 10.1002/dvdy.22109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.22109</ArticleId><ArticleId IdType="pmc">PMC2831750</ArticleId><ArticleId IdType="pubmed">19806666</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Inoue K., Ishii J., Vanti W.B., Voronov S.V., Murchison E., Hannon G., Abeliovich A. A MicroRNA feedback circuit in midbrain dopamine neurons. Science. 2007;317:1220&#x2013;1224. doi: 10.1126/science.1140481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1140481</ArticleId><ArticleId IdType="pmc">PMC2782470</ArticleId><ArticleId IdType="pubmed">17761882</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T., Liu Y., Huang M., Zhao X., Cheng L. Wnt1-cre-mediated conditional loss of Dicer results in malformation of the midbrain and cerebellum and failure of neural crest and dopaminergic differentiation in mice. J. Mol. Cell Biol. 2010;2:152&#x2013;163. doi: 10.1093/jmcb/mjq008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjq008</ArticleId><ArticleId IdType="pubmed">20457670</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis T.H., Cuellar T.L., Koch S.M., Barker A.J., Harfe B.D., McManus M.T., Ullian E.M. Conditional loss of Dicer disrupts cellular and tissue morphogenesis in the cortex and hippocampus. J. Neurosci. 2008;28:4322&#x2013;4330. doi: 10.1523/JNEUROSCI.4815-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4815-07.2008</ArticleId><ArticleId IdType="pmc">PMC3844796</ArticleId><ArticleId IdType="pubmed">18434510</ArticleId></ArticleIdList></Reference><Reference><Citation>De Pietri Tonelli D., Pulvers J.N., Haffner C., Murchison E.P., Hannon G.J., Huttner W.B. miRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex. Development. 2008;135:3911&#x2013;3921. doi: 10.1242/dev.025080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.025080</ArticleId><ArticleId IdType="pmc">PMC2798592</ArticleId><ArticleId IdType="pubmed">18997113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chmielarz P., Konovalova J., Najam S.S., Alter H., Piepponen T.P., Erfle H., Sonntag K.C., Schutz G., Vinnikov I.A., Domanskyi A. Dicer and microRNAs protect adult dopamine neurons. Cell Death Dis. 2017;8:e2813. doi: 10.1038/cddis.2017.214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.214</ArticleId><ArticleId IdType="pmc">PMC5520729</ArticleId><ArticleId IdType="pubmed">28542144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko H., Dridi S., Tarallo V., Gelfand B.D., Fowler B.J., Cho W.G., Kleinman M.E., Ponicsan S.L., Hauswirth W.W., Chiodo V.A., et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature. 2011;471:325&#x2013;330. doi: 10.1038/nature09830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09830</ArticleId><ArticleId IdType="pmc">PMC3077055</ArticleId><ArticleId IdType="pubmed">21297615</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang X., Hogan E.M., Casserly A., Gao G., Gardner P.D., Tapper A.R. Dicer expression is essential for adult midbrain dopaminergic neuron maintenance and survival. Mol. Cell Neurosci. 2014;58:22&#x2013;28. doi: 10.1016/j.mcn.2013.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2013.10.009</ArticleId><ArticleId IdType="pmc">PMC3944994</ArticleId><ArticleId IdType="pubmed">24184162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert S.S., Papadopoulou A.S., Smith P., Galas M.C., Planel E., Silahtaroglu A.N., Sergeant N., Buee L., De Strooper B. Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum. Mol. Genet. 2010;19:3959&#x2013;3969. doi: 10.1093/hmg/ddq311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq311</ArticleId><ArticleId IdType="pubmed">20660113</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer A., O&#x2019;Carroll D., Tan C.L., Hillman D., Sugimori M., Llinas R., Greengard P. Cerebellar neurodegeneration in the absence of microRNAs. J. Exp. Med. 2007;204:1553&#x2013;1558. doi: 10.1084/jem.20070823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20070823</ArticleId><ArticleId IdType="pmc">PMC2118654</ArticleId><ArticleId IdType="pubmed">17606634</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka W., Kiryk A., Novak M., Herwerth M., Parkitna J.R., Wawrzyniak M., Kowarsch A., Michaluk P., Dzwonek J., Arnsperger T., et al. MicroRNA loss enhances learning and memory in mice. J. Neurosci. 2010;30:14835&#x2013;14842. doi: 10.1523/JNEUROSCI.3030-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3030-10.2010</ArticleId><ArticleId IdType="pmc">PMC6633640</ArticleId><ArticleId IdType="pubmed">21048142</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinnikov I.A., Hajdukiewicz K., Reymann J., Beneke J., Czajkowski R., Roth L.C., Novak M., Roller A., D&#xf6;rner N., Starkuviene V., et al. Hypothalamic miR-103 protects from hyperphagic obesity in mice. J. Neurosci. 2014;34:10659&#x2013;10674. doi: 10.1523/JNEUROSCI.4251-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4251-13.2014</ArticleId><ArticleId IdType="pmc">PMC6802591</ArticleId><ArticleId IdType="pubmed">25100599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuellar T.L., Davis T.H., Nelson P.T., Loeb G.B., Harfe B.D., Ullian E., McManus M.T. Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration. Proc. Natl. Acad. Sci. USA. 2008;105:5614&#x2013;5619. doi: 10.1073/pnas.0801689105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0801689105</ArticleId><ArticleId IdType="pmc">PMC2291142</ArticleId><ArticleId IdType="pubmed">18385371</ArticleId></ArticleIdList></Reference><Reference><Citation>Mang G.M., Pradervand S., Du N.H., Arpat A.B., Preitner F., Wigger L., Gatfield D., Franken P. A neuron-specific deletion of the microRNA-processing enzyme DICER induces severe but transient obesity in mice. PLoS ONE. 2015;10:e0116760. doi: 10.1371/journal.pone.0116760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0116760</ArticleId><ArticleId IdType="pmc">PMC4309537</ArticleId><ArticleId IdType="pubmed">25629159</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer A., Im H.I., Veno M.T., Fowler C.D., Min A., Intrator A., Kjems J., Kenny P.J., O&#x2019;Carroll D., Greengard P. Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction. J. Exp. Med. 2010;207:1843&#x2013;1851. doi: 10.1084/jem.20100451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20100451</ArticleId><ArticleId IdType="pmc">PMC2931161</ArticleId><ArticleId IdType="pubmed">20643829</ArticleId></ArticleIdList></Reference><Reference><Citation>Schratt G. microRNAs at the synapse. Nat. Rev. Neurosci. 2009;10:842&#x2013;849. doi: 10.1038/nrn2763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2763</ArticleId><ArticleId IdType="pubmed">19888283</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniou A., Khudayberdiev S., Idziak A., Bicker S., Jacob R., Schratt G. The dynamic recruitment of TRBP to neuronal membranes mediates dendritogenesis during development. EMBO Rep. 2018;19 doi: 10.15252/embr.201744853.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201744853</ArticleId><ArticleId IdType="pmc">PMC5835843</ArticleId><ArticleId IdType="pubmed">29263199</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas K.T., Gross C., Bassell G.J. microRNAs Sculpt Neuronal Communication in a Tight Balance That Is Lost in Neurological Disease. Front. Mol. Neurosci. 2018;11:455. doi: 10.3389/fnmol.2018.00455.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00455</ArticleId><ArticleId IdType="pmc">PMC6299112</ArticleId><ArticleId IdType="pubmed">30618607</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimmeler S., Nicotera P. MicroRNAs in age-related diseases. EMBO Mol. Med. 2013;5:180&#x2013;190. doi: 10.1002/emmm.201201986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201986</ArticleId><ArticleId IdType="pmc">PMC3569636</ArticleId><ArticleId IdType="pubmed">23339066</ArticleId></ArticleIdList></Reference><Reference><Citation>Eacker S.M., Dawson T.M., Dawson V.L. Understanding microRNAs in neurodegeneration. Nat. Rev. Neurosci. 2009;10:837&#x2013;841. doi: 10.1038/nrn2726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2726</ArticleId><ArticleId IdType="pmc">PMC4120241</ArticleId><ArticleId IdType="pubmed">19904280</ArticleId></ArticleIdList></Reference><Reference><Citation>Eacker S.M., Dawson T.M., Dawson V.L. The interplay of microRNA and neuronal activity in health and disease. Front. Cell Neurosci. 2013;7:136. doi: 10.3389/fncel.2013.00136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00136</ArticleId><ArticleId IdType="pmc">PMC3753455</ArticleId><ArticleId IdType="pubmed">23986658</ArticleId></ArticleIdList></Reference><Reference><Citation>Heman-Ackah S.M., Hallegger M., Rao M.S., Wood M.J. RISC in PD: The impact of microRNAs in Parkinson&#x2019;s disease cellular and molecular pathogenesis. Front. Mol. Neurosci. 2013;6:40. doi: 10.3389/fnmol.2013.00040.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2013.00040</ArticleId><ArticleId IdType="pmc">PMC3834244</ArticleId><ArticleId IdType="pubmed">24312000</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouradian M.M. MicroRNAs in Parkinson&#x2019;s disease. Neurobiol. Dis. 2012;46:279&#x2013;284. doi: 10.1016/j.nbd.2011.12.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.12.046</ArticleId><ArticleId IdType="pubmed">22245218</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonntag K.C. MicroRNAs and deregulated gene expression networks in neurodegeneration. Brain Res. 2010;1338:48&#x2013;57. doi: 10.1016/j.brainres.2010.03.106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2010.03.106</ArticleId><ArticleId IdType="pmc">PMC2883630</ArticleId><ArticleId IdType="pubmed">20380815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurzynska-Kokorniak A., Koralewska N., Pokornowska M., Urbanowicz A., Tworak A., Mickiewicz A., Figlerowicz M. The many faces of Dicer: The complexity of the mechanisms regulating Dicer gene expression and enzyme activities. Nucleic Acids Res. 2015;43:4365&#x2013;4380. doi: 10.1093/nar/gkv328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv328</ArticleId><ArticleId IdType="pmc">PMC4482082</ArticleId><ArticleId IdType="pubmed">25883138</ArticleId></ArticleIdList></Reference><Reference><Citation>Leggio L., Vivarelli S., L&#x2019;Episcopo F., Tirolo C., Caniglia S., Testa N., Marchetti B., Iraci N. microRNAs in Parkinson&#x2019;s disease: From pathogenesis to novel diagnostic and therapeutic approaches. Int. J. Mol. Sci. 2017;18:2698. doi: 10.3390/ijms18122698.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18122698</ArticleId><ArticleId IdType="pmc">PMC5751299</ArticleId><ArticleId IdType="pubmed">29236052</ArticleId></ArticleIdList></Reference><Reference><Citation>Emde A., Hornstein E. miRNAs at the interface of cellular stress and disease. EMBO J. 2014;33:1428&#x2013;1437. doi: 10.15252/embj.201488142.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201488142</ArticleId><ArticleId IdType="pmc">PMC4194087</ArticleId><ArticleId IdType="pubmed">24867813</ArticleId></ArticleIdList></Reference><Reference><Citation>Emde A., Eitan C., Liou L.L., Libby R.T., Rivkin N., Magen I., Reichenstein I., Oppenheim H., Eilam R., Silvestroni A., et al. Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: A new mechanism for ALS. EMBO J. 2015;34:2633&#x2013;2651. doi: 10.15252/embj.201490493.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201490493</ArticleId><ArticleId IdType="pmc">PMC4641530</ArticleId><ArticleId IdType="pubmed">26330466</ArticleId></ArticleIdList></Reference><Reference><Citation>Engedal N., Zerovnik E., Rudov A., Galli F., Olivieri F., Procopio A.D., Rippo M.R., Monsurro V., Betti M., Albertini M.C. From oxidative stress damage to pathways, networks, and autophagy via MicroRNAs. Oxid. Med. Cell Longev. 2018;2018:4968321. doi: 10.1155/2018/4968321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4968321</ArticleId><ArticleId IdType="pmc">PMC5932428</ArticleId><ArticleId IdType="pubmed">29849898</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinnikov I.A., Domanskyi A. Can we treat neurodegenerative diseases by preventing an age-related decline in microRNA expression? Neural Regen. Res. 2017;12:1602&#x2013;1604. doi: 10.4103/1673-5374.217328.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.217328</ArticleId><ArticleId IdType="pmc">PMC5696834</ArticleId><ArticleId IdType="pubmed">29171418</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmena L., Poliseno L., Tay Y., Kats L., Pandolfi P.P. A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell. 2011;146:353&#x2013;358. doi: 10.1016/j.cell.2011.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.07.014</ArticleId><ArticleId IdType="pmc">PMC3235919</ArticleId><ArticleId IdType="pubmed">21802130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumazin P., Yang X., Chiu H.S., Chung W.J., Iyer A., Llobet-Navas D., Rajbhandari P., Bansal M., Guarnieri P., Silva J., et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011;147:370&#x2013;381. doi: 10.1016/j.cell.2011.09.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.09.041</ArticleId><ArticleId IdType="pmc">PMC3214599</ArticleId><ArticleId IdType="pubmed">22000015</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M., Ali G.-C., Guerchet M., Prina A.M., Albanese E., Wu Y.-T. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimer&#x2019;s Res. Ther. 2016;8:23. doi: 10.1186/s13195-016-0188-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-016-0188-8</ArticleId><ArticleId IdType="pmc">PMC4967299</ArticleId><ArticleId IdType="pubmed">27473681</ArticleId></ArticleIdList></Reference><Reference><Citation>Tramutola A., Lanzillotta C., Perluigi M., Butterfield D.A. Oxidative stress, protein modification and Alzheimer disease. Brain Res. Bull. 2017;133:88&#x2013;96. doi: 10.1016/j.brainresbull.2016.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2016.06.005</ArticleId><ArticleId IdType="pubmed">27316747</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cauwenberghe C., Van Broeckhoven C., Sleegers K. The genetic landscape of Alzheimer disease: Clinical implications and perspectives. Genetics Med. 2015;18:421. doi: 10.1038/gim.2015.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.117</ArticleId><ArticleId IdType="pmc">PMC4857183</ArticleId><ArticleId IdType="pubmed">26312828</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C., De Ronchi D., Fratiglioni L. The epidemiology of the dementias: An update. Curr. Opin. Psychiatry. 2007;20:380&#x2013;385. doi: 10.1097/YCO.0b013e32816ebc7b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0b013e32816ebc7b</ArticleId><ArticleId IdType="pubmed">17551353</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad K.N. Oxidative stress and pro-inflammatory cytokines may act as one of the signals for regulating microRNAs expression in Alzheimer&#x2019;s disease. Mech. Ageing Dev. 2017;162:63&#x2013;71. doi: 10.1016/j.mad.2016.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2016.12.003</ArticleId><ArticleId IdType="pubmed">27964992</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanoisel&#xe9;e H.-M., Nicolas G., Wallon D., Rovelet-Lecrux A., Lacour M., Rousseau S., Richard A.-C., Pasquier F., Rollin-Sillaire A., Martinaud O., et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med. 2017;14:e1002270. doi: 10.1371/journal.pmed.1002270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002270</ArticleId><ArticleId IdType="pmc">PMC5370101</ArticleId><ArticleId IdType="pubmed">28350801</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel N., Hoang D., Miller N., Ansaloni S., Huang Q., Rogers J.T., Lee J.C., Saunders A.J. MicroRNAs can regulate human APP levels. Mol. Neurodegener. 2008;3:10. doi: 10.1186/1750-1326-3-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-3-10</ArticleId><ArticleId IdType="pmc">PMC2529281</ArticleId><ArticleId IdType="pubmed">18684319</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert S.S., Horr&#xe9; K., Nicola&#xef; L., Bergmans B., Papadopoulou A.S., Delacourte A., De Strooper B. MicroRNA regulation of Alzheimer&#x2019;s Amyloid precursor protein expression. Neurobiol. Dis. 2009;33:422&#x2013;428. doi: 10.1016/j.nbd.2008.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.11.009</ArticleId><ArticleId IdType="pubmed">19110058</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.G., Wang J.L., Li L., Xue L.X., Zhang Y.Q., Wang P.C. MicroRNA-135a and -200b, potential Biomarkers for Alzheimer&#x5f3;s disease, regulate &#x3b2; secretase and amyloid precursor protein. Brain Res. 2014;1583:55&#x2013;64. doi: 10.1016/j.brainres.2014.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2014.04.026</ArticleId><ArticleId IdType="pubmed">25152461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Q., Xiang Y., Li D., Liang J., Zhang X., Zhou F., Qiao M., Nie Y., He Y., Cheng J., et al. MiR-124-3p attenuates hyperphosphorylation of Tau protein-induced apoptosis via caveolin-1-PI3K/Akt/GSK3&#x3b2; pathway in N2a/APP695swe cells. Oncotarget. 2017;8:24314&#x2013;24326. doi: 10.18632/oncotarget.15149.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.15149</ArticleId><ArticleId IdType="pmc">PMC5421849</ArticleId><ArticleId IdType="pubmed">28186985</ArticleId></ArticleIdList></Reference><Reference><Citation>Long J.M., Ray B., Lahiri D.K. MicroRNA-153 physiologically inhibits expression of amyloid-&#x3b2; precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J. Biol. Chem. 2012;287:31298&#x2013;31310. doi: 10.1074/jbc.M112.366336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.366336</ArticleId><ArticleId IdType="pmc">PMC3438960</ArticleId><ArticleId IdType="pubmed">22733824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Tan L., Lu Y., Peng J., Zhu Y., Zhang Y., Sun Z. MicroRNA-138 promotes tau phosphorylation by targeting retinoic acid receptor alpha. FEBS Lett. 2015;589:726&#x2013;729. doi: 10.1016/j.febslet.2015.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2015.02.001</ArticleId><ArticleId IdType="pubmed">25680531</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad K.N. Simultaneous activation of Nrf2 and elevation of antioxidant compounds for reducing oxidative stress and chronic inflammation in human Alzheimer&#x2019;s disease. Mech. Ageing Dev. 2016;153:41&#x2013;47. doi: 10.1016/j.mad.2016.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2016.01.002</ArticleId><ArticleId IdType="pubmed">26811881</ArticleId></ArticleIdList></Reference><Reference><Citation>Amakiri N., Kubosumi A., Tran J., Reddy P.H. Amyloid beta and microRNAs in Alzheimer&#x2019;s disease. Front. Neurosci. 2019;13 doi: 10.3389/fnins.2019.00430.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00430</ArticleId><ArticleId IdType="pmc">PMC6510214</ArticleId><ArticleId IdType="pubmed">31130840</ArticleId></ArticleIdList></Reference><Reference><Citation>Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Review: Alzheimer&#x2019;s amyloid &#x3b2;-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 2000;130:184&#x2013;208. doi: 10.1006/jsbi.2000.4274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jsbi.2000.4274</ArticleId><ArticleId IdType="pubmed">10940225</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.J., Dolios G., Wang R., Liao F.-F. Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal icroRNA expression. PLoS ONE. 2014;9:e90770. doi: 10.1371/journal.pone.0090770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090770</ArticleId><ArticleId IdType="pmc">PMC3942478</ArticleId><ArticleId IdType="pubmed">24595404</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W.-X., Rajeev B.W., Stromberg A.J., Ren N., Tang G., Huang Q., Rigoutsos I., Nelson P.T. The expression of microRNA miR-107 decreases early in Alzheimer&#x2019;s disease and may accelerate disease progression through regulation of &#x3b2;-site amyloid precursor protein-cleaving enzyme 1. J. Neurosci. 2008;28:1213&#x2013;1223. doi: 10.1523/JNEUROSCI.5065-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5065-07.2008</ArticleId><ArticleId IdType="pmc">PMC2837363</ArticleId><ArticleId IdType="pubmed">18234899</ArticleId></ArticleIdList></Reference><Reference><Citation>Monte S., Wands J. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer&#x2019;s disease. J. Alzheimer&#x2019;s Dis. 2006;9:167&#x2013;181. doi: 10.3233/JAD-2006-9209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2006-9209</ArticleId><ArticleId IdType="pubmed">16873964</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorszewska J., Oczkowska A., Suwalska M., Rozycka A., Florczak-Wyspianska J., Dezor M., Lianeri M., Jagodzinski P.P., Kowalczyk M.J., Prendecki M., et al. Mutations in the exon 7 of Trp53 gene and the level of p53 protein in double transgenic mouse model of Alzheimer&#x2019;s disease. Folia Neuropathol. 2014;52:30&#x2013;40. doi: 10.5114/fn.2014.41742.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/fn.2014.41742</ArticleId><ArticleId IdType="pubmed">24729341</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorszewska J., Oczkowska A., Suwalska M., Rozycka A., Florczak J., Dezor M., Lianeri M., Jagodzinski P., Kowalczyk M., Prendecki M., et al. Mutations of TP53 gene and oxidative stress in Alzheimer&#x2019;s disease patients. Adv. Alzheimer&#x2019;s Dis. 2014;3:24&#x2013;32. doi: 10.4236/aad.2014.31004.</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/aad.2014.31004</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Zhang R., Li P., Liu Y., Qin K., Fa Z.Q., Liu Y.J., Ke Y.Q., Jiang X.D. P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2. Neurosci. Lett. 2013;534:327&#x2013;332. doi: 10.1016/j.neulet.2012.11.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2012.11.047</ArticleId><ArticleId IdType="pubmed">23220650</ArticleId></ArticleIdList></Reference><Reference><Citation>Prendecki M., Florczak-Wyspianska J., Kowalska M., Ilkowski J., Grzelak T., Bialas K., Kozubski W., Dorszewska J. APOE genetic variants and apoE, miR-107 and miR-650 levels in Alzheimer&#x2019;s disease. Folia Neuropathol. 2019;57:106&#x2013;116. doi: 10.5114/fn.2019.84828.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/fn.2019.84828</ArticleId><ArticleId IdType="pubmed">31556571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Yoon H., Chung D.E., Brown J.L., Belmonte K.C., Kim J. miR-186 is decreased in aged brain and suppresses BACE1 expression. J. Neurochem. 2016;137:436&#x2013;445. doi: 10.1111/jnc.13507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13507</ArticleId><ArticleId IdType="pmc">PMC4837067</ArticleId><ArticleId IdType="pubmed">26710318</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Wu Y., Gu M., Zhang Y. MiR-342-5p decreases ankyrin G levels in Alzheimer&#x2019;s disease transgenic mouse models. Cell Rep. 2014;6:264&#x2013;270. doi: 10.1016/j.celrep.2013.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.12.028</ArticleId><ArticleId IdType="pubmed">24440716</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang C., Zhu H., Xu Y., Huang L., Ma C., Deng W., Liu Y., Qin C. MicroRNA-153 negatively regulates the expression of amyloid precursor protein and amyloid precursor-like protein 2. Brain Res. 2012;1455:103&#x2013;113. doi: 10.1016/j.brainres.2011.10.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.10.051</ArticleId><ArticleId IdType="pubmed">22510281</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X.D., Sun G.L., Zhou T.T., Wang Y.Y., Xu X., Shi X.F., Zhu Z.Y., Rukachaisirikul V., Hu L.H., Shen X. LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy. Acta Pharmacol. Sin. 2017;38:1104&#x2013;1119. doi: 10.1038/aps.2016.128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2016.128</ArticleId><ArticleId IdType="pmc">PMC5547549</ArticleId><ArticleId IdType="pubmed">28649128</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A., Kaarniranta K., Kauppinen A. Crosstalk between oxidative stress and SIRT1: Impact on the aging process. Int. J. Mol. Sci. 2013;14:3834&#x2013;3859. doi: 10.3390/ijms14023834.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms14023834</ArticleId><ArticleId IdType="pmc">PMC3588074</ArticleId><ArticleId IdType="pubmed">23434668</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias-Santagata D., Fulga T.A., Duttaroy A., Feany M.B. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J. Clin. Investig. 2007;117:236&#x2013;245. doi: 10.1172/JCI28769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI28769</ArticleId><ArticleId IdType="pmc">PMC1697799</ArticleId><ArticleId IdType="pubmed">17173140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Liu J., Wang Q., Jiang H., Zeng L., Li Z., Liu R. MicroRNA-200a-3p mediates neuroprotection in Alzheimer-related deficits and attenuates amyloid-beta overproduction and tau hyperphosphorylation via coregulating BACE1 and PRKACB. Front. Pharmacol. 2019;10 doi: 10.3389/fphar.2019.00806.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00806</ArticleId><ArticleId IdType="pmc">PMC6658613</ArticleId><ArticleId IdType="pubmed">31379578</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Chen W., Yi Y., Tong Q. miR-219-5p inhibits tau phosphorylation by targeting TTBK1 and GSK-3&#x3b2; in Alzheimer&#x2019;s disease. J. Cell. Biochem. 2019;120:9936&#x2013;9946. doi: 10.1002/jcb.28276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.28276</ArticleId><ArticleId IdType="pubmed">30556160</ArticleId></ArticleIdList></Reference><Reference><Citation>El Fatimy R., Li S., Chen Z., Mushannen T., Gongala S., Wei Z., Balu D.T., Rabinovsky R., Cantlon A., Elkhal A., et al. MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. Acta Neuropathol. 2018;136:537&#x2013;555. doi: 10.1007/s00401-018-1880-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1880-5</ArticleId><ArticleId IdType="pmc">PMC6132948</ArticleId><ArticleId IdType="pubmed">29982852</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith P.Y., Hernandez-Rapp J., Jolivette F., Lecours C., Bisht K., Goupil C., Dorval V., Parsi S., Morin F., Planel E., et al. MiR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum. Mol. Gen. 2015;24:6721&#x2013;6735. doi: 10.1093/hmg/ddv377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv377</ArticleId><ArticleId IdType="pmc">PMC4634376</ArticleId><ArticleId IdType="pubmed">26362250</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Huang Y., Wang L.-L., Zhang Y.-F., Xu J., Zhou Y., Lourenco G.F., Zhang B., Wang Y., Ren R.-J., et al. MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer&#x2019;s disease. Sci. Rep. 2016;6:26697. doi: 10.1038/srep26697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep26697</ArticleId><ArticleId IdType="pmc">PMC4879631</ArticleId><ArticleId IdType="pubmed">27221467</ArticleId></ArticleIdList></Reference><Reference><Citation>Absalon S., Kochanek D.M., Raghavan V., Krichevsky A.M. MiR-26b, upregulated in Alzheimer&#x2019;s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J. Neurosci. 2013;33:14645&#x2013;14659. doi: 10.1523/JNEUROSCI.1327-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1327-13.2013</ArticleId><ArticleId IdType="pmc">PMC3810537</ArticleId><ArticleId IdType="pubmed">24027266</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R., Zhang Q., Niu J., Lu K., Xie B., Cui D., Xu S. Screening of microRNAs associated with Alzheimer&#x2019;s disease using oxidative stress cell model and different strains of senescence accelerated mice. J. Neurol. Sci. 2014;338:57&#x2013;64. doi: 10.1016/j.jns.2013.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2013.12.017</ArticleId><ArticleId IdType="pubmed">24423585</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Wang Z.-F., Li W., Hong H., Chen J., Tian Y., Liu Z.-Y. Protective effects of microRNA-330 on amyloid &#x3b2;-protein production, oxidative stress, and mitochondrial dysfunction in Alzheimer&#x2019;s disease by targeting VAV1 via the MAPK signaling pathway. J. Cell. Biochem. 2018;119:5437&#x2013;5448. doi: 10.1002/jcb.26700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.26700</ArticleId><ArticleId IdType="pubmed">29369410</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Foruria I., Santulli P., Chouzenoux S., Carmona F., Chapron C., Batteux F. Dysregulation of the ADAM17/Notch signalling pathways in endometriosis: From oxidative stress to fibrosis. Mol. Hum. Reprod. 2017;23:488&#x2013;499. doi: 10.1093/molehr/gax028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molehr/gax028</ArticleId><ArticleId IdType="pubmed">28486700</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao W.E., Wei J.F., Kong Y.G., Xu Y., Tao Z.Z., Chen S.M. Notch signaling promotes development of allergic rhinitis by suppressing Foxp3 expression and treg cell differentiation. Int. Arch. Allergy Immunol. 2019;178:33&#x2013;44. doi: 10.1159/000493328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000493328</ArticleId><ArticleId IdType="pubmed">30391960</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu P., Yang M., He H., Kuang Z., Liang M., Lin A., Liang S., Wen Q., Cheng Z., Sun C. Curcumin attenuates hypoxia/reoxygenationinduced cardiomyocyte injury by downregulating Notch signaling. Mol. Med. Rep. 2019;20:1541&#x2013;1550. doi: 10.3892/mmr.2019.10371.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2019.10371</ArticleId><ArticleId IdType="pmc">PMC6625400</ArticleId><ArticleId IdType="pubmed">31257466</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F.-Z., Zhao Y., Chen H.-Z. MicroRNA-98 reduces amyloid &#x3b2;-protein production and improves oxidative stress and mitochondrial dysfunction through the Notch signaling pathway via HEY2 in Alzheimer&#x2019;s disease mice. Int. J. Mol. Med. 2019;43:91&#x2013;102. doi: 10.3892/ijmm.2018.3957.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2018.3957</ArticleId><ArticleId IdType="pmc">PMC6257854</ArticleId><ArticleId IdType="pubmed">30365070</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Dong H., Si Y., Wu N., Cao H., Mei B., Meng B. miR-125b promotes tau phosphorylation by targeting the neural cell adhesion molecule in neuropathological progression. Neurobiol. Aging. 2019;73:41&#x2013;49. doi: 10.1016/j.neurobiolaging.2018.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.09.011</ArticleId><ArticleId IdType="pubmed">30316051</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Tu Q., Liu M. MicroRNA125b regulates Alzheimer&#x2019;s disease through SphK1 regulation. Mol. Med. Rep. 2018;18:2373&#x2013;2380. doi: 10.3892/mmr.2018.9156.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2018.9156</ArticleId><ArticleId IdType="pubmed">29901156</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D.-M., Wen X., Wang Y.-J., Han X.-R., Wang S., Shen M., Fan S.-H., Zhuang J., Zhang Z.-F., Shan Q., et al. Effect of microRNA-186 on oxidative stress injury of neuron by targeting interleukin 2 through the janus kinase-signal transducer and activator of transcription pathway in a rat model of Alzheime&#x2019;s disease. J. Cell. Physiol. 2018;233:9488&#x2013;9502. doi: 10.1002/jcp.26843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.26843</ArticleId><ArticleId IdType="pubmed">29995978</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger K.A. Neuropathobiology of non-motor symptoms in Parkinson disease. J. Neural Transm. 2015;122:1429&#x2013;1440. doi: 10.1007/s00702-015-1405-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-015-1405-5</ArticleId><ArticleId IdType="pubmed">25976432</ArticleId></ArticleIdList></Reference><Reference><Citation>Tysnes O.B., Storstein A. Epidemiology of Parkinson&#x2019;s disease. J. Neural Transm. 2017;124:901&#x2013;905. doi: 10.1007/s00702-017-1686-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1686-y</ArticleId><ArticleId IdType="pubmed">28150045</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z., Li X., Li X., Liu Q., Cheng Y. Oxidative stress in Parkinson&#x2019;s disease: A systematic review and meta-analysis. Front. Mol. Neurosci. 2018;11:236. doi: 10.3389/fnmol.2018.00236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00236</ArticleId><ArticleId IdType="pmc">PMC6041404</ArticleId><ArticleId IdType="pubmed">30026688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang D.Y., Hong S., Jeong J.W., Choi S., Kim H., Kim J., Kim K.S. Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons. J. Neurochem. 2009;111:1202&#x2013;1212. doi: 10.1111/j.1471-4159.2009.06404.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06404.x</ArticleId><ArticleId IdType="pmc">PMC4896488</ArticleId><ArticleId IdType="pubmed">19780901</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Li C., Chen Z., He J., Tao Z., Yin Z.Q. A microRNA, mir133b, suppresses melanopsin expression mediated by failure dopaminergic amacrine cells in RCS rats. Cell Signal. 2012;24:685&#x2013;698. doi: 10.1016/j.cellsig.2011.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2011.10.017</ArticleId><ArticleId IdType="pubmed">22101014</ArticleId></ArticleIdList></Reference><Reference><Citation>Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., Colebrooke R.E., Di Monte D.A., Emson P.C., Miller G.W. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 2007;27:8138&#x2013;8148. doi: 10.1523/JNEUROSCI.0319-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0319-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672727</ArticleId><ArticleId IdType="pubmed">17652604</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoud S.T., Vecchio L.M., Bergeron Y., Hossain M.M., Nguyen L.T., Bermejo M.K., Kile B., Sotnikova T.D., Siesser W.B., Gainetdinov R.R., et al. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiol. Dis. 2015;74:66&#x2013;75. doi: 10.1016/j.nbd.2014.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.10.016</ArticleId><ArticleId IdType="pmc">PMC4505366</ArticleId><ArticleId IdType="pubmed">25447236</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X., Wang F., Han Y., Geng X., Li M., Shi Y., Lu L., Chen Y. MiR-137 and miR-491 negatively regulate dopamine transporter expression and function in neural cells. Neurosci. Bull. 2016;32:512&#x2013;522. doi: 10.1007/s12264-016-0061-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-016-0061-6</ArticleId><ArticleId IdType="pmc">PMC5563834</ArticleId><ArticleId IdType="pubmed">27628529</ArticleId></ArticleIdList></Reference><Reference><Citation>Barodia S.K., Creed R.B., Goldberg M.S. Parkin and PINK1 functions in oxidative stress and neurodegeneration. Brain Res. Bull. 2017;133:51&#x2013;59. doi: 10.1016/j.brainresbull.2016.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2016.12.004</ArticleId><ArticleId IdType="pmc">PMC5718625</ArticleId><ArticleId IdType="pubmed">28017782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.L., Chou A.H., Wu A.S., Chen S.Y., Weng Y.H., Kao Y.C., Yeh T.H., Chu P.J., Lu C.S. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochim. Biophys. Acta. 2011;1812:674&#x2013;684. doi: 10.1016/j.bbadis.2011.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2011.03.007</ArticleId><ArticleId IdType="pubmed">21421046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood-Kaczmar A., Gandhi S., Yao Z., Abramov A.Y., Miljan E.A., Keen G., Stanyer L., Hargreaves I., Klupsch K., Deas E., et al. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS ONE. 2008;3:e2455. doi: 10.1371/annotation/ba489c2a-5cf2-481c-aff7-d2c8c4ecdcfa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/annotation/ba489c2a-5cf2-481c-aff7-d2c8c4ecdcfa</ArticleId><ArticleId IdType="pmc">PMC2413012</ArticleId><ArticleId IdType="pubmed">18560593</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Fiesel F.C., Belmonte K.C., Hudec R., Wang W.X., Kim C., Nelson P.T., Springer W., Kim J. miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1) Mol. Neurodegener. 2016;11:55. doi: 10.1186/s13024-016-0121-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0121-4</ArticleId><ArticleId IdType="pmc">PMC4960690</ArticleId><ArticleId IdType="pubmed">27456084</ArticleId></ArticleIdList></Reference><Reference><Citation>Prajapati P., Sripada L., Singh K., Bhatelia K., Singh R., Singh R. TNF-alpha regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells. Biochim. Biophys. Acta. 2015;1852:451&#x2013;461. doi: 10.1016/j.bbadis.2014.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2014.11.019</ArticleId><ArticleId IdType="pubmed">25481834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T., Ishimori C., Takahashi-Niki K., Taira T., Kim Y.C., Maita H., Maita C., Ariga H., Iguchi-Ariga S.M. DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem. Biophys. Res. Commun. 2009;390:667&#x2013;672. doi: 10.1016/j.bbrc.2009.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.10.025</ArticleId><ArticleId IdType="pubmed">19822128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariga H., Takahashi-Niki K., Kato I., Maita H., Niki T., Iguchi-Ariga S.M. Neuroprotective function of DJ-1 in Parkinson&#x2019;s disease. Oxid. Med. Cell Longev. 2013;2013:683920. doi: 10.1155/2013/683920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/683920</ArticleId><ArticleId IdType="pmc">PMC3671546</ArticleId><ArticleId IdType="pubmed">23766857</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J., Sullards M.C., Olzmann J.A., Rees H.D., Weintraub S.T., Bostwick D.E., Gearing M., Levey A.I., Chin L.S., Li L. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem. 2006;281:10816&#x2013;10824. doi: 10.1074/jbc.M509079200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M509079200</ArticleId><ArticleId IdType="pmc">PMC1850953</ArticleId><ArticleId IdType="pubmed">16517609</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong R., Wang Z., Zhao Z., Li H., Chen W., Zhang B., Wang L., Wu L., Li W., Ding J., et al. MicroRNA-494 reduces DJ-1 expression and exacerbates neurodegeneration. Neurobiol. Aging. 2014;35:705&#x2013;714. doi: 10.1016/j.neurobiolaging.2013.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.09.027</ArticleId><ArticleId IdType="pubmed">24269020</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Gao C., Sun Q., Pan H., Huang P., Ding J., Chen S. MicroRNA-4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson&#x2019;s disease. Front. Aging Neurosci. 2017;9:232. doi: 10.3389/fnagi.2017.00232.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00232</ArticleId><ArticleId IdType="pmc">PMC5519626</ArticleId><ArticleId IdType="pubmed">28785216</ArticleId></ArticleIdList></Reference><Reference><Citation>Minones-Moyano E., Porta S., Escaramis G., Rabionet R., Iraola S., Kagerbauer B., Espinosa-Parrilla Y., Ferrer I., Estivill X., Marti E. MicroRNA profiling of Parkinson&#x2019;s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum. Mol. Genet. 2011;20:3067&#x2013;3078. doi: 10.1093/hmg/ddr210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr210</ArticleId><ArticleId IdType="pubmed">21558425</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsey C.P., Glass C.A., Montgomery M.B., Lindl K.A., Ritson G.P., Chia L.A., Hamilton R.L., Chu C.T., Jordan-Sciutto K.L. Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 2007;66:75&#x2013;85. doi: 10.1097/nen.0b013e31802d6da9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31802d6da9</ArticleId><ArticleId IdType="pmc">PMC2253896</ArticleId><ArticleId IdType="pubmed">17204939</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Chen Y. MicroRNAs: Emerging targets regulating oxidative stress in the models of Parkinson&#x2019;s disease. Front. Neurosci. 2016;10:298. doi: 10.3389/fnins.2016.00298.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2016.00298</ArticleId><ArticleId IdType="pmc">PMC4923223</ArticleId><ArticleId IdType="pubmed">27445669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabaria S., Choi D.C., Chaudhuri A.D., Jain M.R., Li H., Junn E. MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression. Free Radic. Biol. Med. 2015;89:548&#x2013;556. doi: 10.1016/j.freeradbiomed.2015.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.09.010</ArticleId><ArticleId IdType="pmc">PMC4684759</ArticleId><ArticleId IdType="pubmed">26453926</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan K.J., Murray T.K., Bengoa-Vergniory N., Cordero-Llana O., Cooper J., Buckley A., Wade-Martins R., Uney J.B., O&#x2019;Neill M.J., Wong L.F., et al. Loss of MicroRNA-7 regulation leads to alpha-synuclein accumulation and dopaminergic neuronal loss in vivo. Mol. Ther. 2017;25:2404&#x2013;2414. doi: 10.1016/j.ymthe.2017.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.08.017</ArticleId><ArticleId IdType="pmc">PMC5628933</ArticleId><ArticleId IdType="pubmed">28927576</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan M., Patel D., Vedpathak D., Rathinam M., Henderson G., Mahimainathan L. Identification of novel microRNAs in post-transcriptional control of Nrf2 expression and redox homeostasis in neuronal, SH-SY5Y cells. PLoS ONE. 2012;7:e51111. doi: 10.1371/journal.pone.0051111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0051111</ArticleId><ArticleId IdType="pmc">PMC3517581</ArticleId><ArticleId IdType="pubmed">23236440</ArticleId></ArticleIdList></Reference><Reference><Citation>Slota J.A., Booth S.A. MicroRNAs in neuroinflammation: Implications in disease pathogenesis, biomarker discovery and therapeutic applications. Noncoding RNA. 2019;5:35. doi: 10.3390/ncrna5020035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ncrna5020035</ArticleId><ArticleId IdType="pmc">PMC6632112</ArticleId><ArticleId IdType="pubmed">31022830</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer M.J. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat. Rev. Genet. 2006;7:306&#x2013;318. doi: 10.1038/nrg1831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg1831</ArticleId><ArticleId IdType="pubmed">16543934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M., Masliah E. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 2000;157:401&#x2013;410. doi: 10.1016/S0002-9440(10)64553-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64553-1</ArticleId><ArticleId IdType="pmc">PMC1850140</ArticleId><ArticleId IdType="pubmed">10934145</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., Lee M.K. Parkinson&#x2019;s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 2006;26:41&#x2013;50. doi: 10.1523/JNEUROSCI.4308-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4308-05.2006</ArticleId><ArticleId IdType="pmc">PMC6381830</ArticleId><ArticleId IdType="pubmed">16399671</ArticleId></ArticleIdList></Reference><Reference><Citation>Perfeito R., Ribeiro M., Rego A.C. Alpha-synuclein-induced oxidative stress correlates with altered superoxide dismutase and glutathione synthesis in human neuroblastoma SH-SY5Y cells. Arch. Toxicol. 2017;91:1245&#x2013;1259. doi: 10.1007/s00204-016-1788-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00204-016-1788-6</ArticleId><ArticleId IdType="pubmed">27424009</ArticleId></ArticleIdList></Reference><Reference><Citation>Deas E., Cremades N., Angelova P.R., Ludtmann M.H., Yao Z., Chen S., Horrocks M.H., Banushi B., Little D., Devine M.J., et al. Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson&#x2019;s disease. Antioxid. Redox Signal. 2016;24:376&#x2013;391. doi: 10.1089/ars.2015.6343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2015.6343</ArticleId><ArticleId IdType="pmc">PMC4999647</ArticleId><ArticleId IdType="pubmed">26564470</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Maio R., Barrett P.J., Hoffman E.K., Barrett C.W., Zharikov A., Borah A., Hu X., McCoy J., Chu C.T., Burton E.A., et al. alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson&#x2019;s disease. Sci. Transl. Med. 2016;8:342ra378. doi: 10.1126/scitranslmed.aaf3634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf3634</ArticleId><ArticleId IdType="pmc">PMC5016095</ArticleId><ArticleId IdType="pubmed">27280685</ArticleId></ArticleIdList></Reference><Reference><Citation>Junn E., Lee K.W., Jeong B.S., Chan T.W., Im J.Y., Mouradian M.M. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. USA. 2009;106:13052&#x2013;13057. doi: 10.1073/pnas.0906277106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0906277106</ArticleId><ArticleId IdType="pmc">PMC2722353</ArticleId><ArticleId IdType="pubmed">19628698</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z.H., Zhang J.L., Duan Y.L., Zhang Q.S., Li G.F., Zheng D.L. MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting alpha-synuclein expression in MPTP-induced Parkinson&#x2019;s disease mouse. Biomed. Pharmacother. 2015;74:252&#x2013;256. doi: 10.1016/j.biopha.2015.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2015.08.025</ArticleId><ArticleId IdType="pubmed">26349993</ArticleId></ArticleIdList></Reference><Reference><Citation>Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J. Biol. Chem. 2010;285:12726&#x2013;12734. doi: 10.1074/jbc.M109.086827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.086827</ArticleId><ArticleId IdType="pmc">PMC2857101</ArticleId><ArticleId IdType="pubmed">20106983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabaria S., Choi D.C., Chaudhuri A.D., Mouradian M.M., Junn E. Inhibition of miR-34b and miR-34c enhances alpha-synuclein expression in Parkinson&#x2019;s disease. FEBS Lett. 2015;589:319&#x2013;325. doi: 10.1016/j.febslet.2014.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2014.12.014</ArticleId><ArticleId IdType="pmc">PMC4306645</ArticleId><ArticleId IdType="pubmed">25541488</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Erviti L., Seow Y., Schapira A.H., Rodriguez-Oroz M.C., Obeso J.A., Cooper J.M. Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson&#x2019;s disease. Cell Death Dis. 2013;4:e545. doi: 10.1038/cddis.2013.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.73</ArticleId><ArticleId IdType="pmc">PMC3615743</ArticleId><ArticleId IdType="pubmed">23492776</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Yang H., Zhu D., Huang H., Liu G., Lun P. Targeted suppression of chaperone-mediated autophagy by miR-320a promotes alpha-synuclein aggregation. Int. J. Mol. Sci. 2014;15:15845&#x2013;15857. doi: 10.3390/ijms150915845.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms150915845</ArticleId><ArticleId IdType="pmc">PMC4200851</ArticleId><ArticleId IdType="pubmed">25207598</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Cheng Y. miR-16-1 promotes the aberrant alpha-synuclein accumulation in parkinson disease via targeting heat shock protein 70. Sci. World J. 2014;2014:938348. doi: 10.1155/2014/938348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/938348</ArticleId><ArticleId IdType="pmc">PMC4094852</ArticleId><ArticleId IdType="pubmed">25054189</ArticleId></ArticleIdList></Reference><Reference><Citation>Recasens A., Perier C., Sue C.M. Role of microRNAs in the Regulation of alpha-Synuclein Expression: A Systematic Review. Front. Mol. Neurosci. 2016;9:128. doi: 10.3389/fnmol.2016.00128.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2016.00128</ArticleId><ArticleId IdType="pmc">PMC5116472</ArticleId><ArticleId IdType="pubmed">27917109</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias V., Junn E., Mouradian M.M. The role of oxidative stress in Parkinson&#x2019;s disease. J. Parkinsons Dis. 2013;3:461&#x2013;491. doi: 10.3233/JPD-130230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-130230</ArticleId><ArticleId IdType="pmc">PMC4135313</ArticleId><ArticleId IdType="pubmed">24252804</ArticleId></ArticleIdList></Reference><Reference><Citation>Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007;8:57&#x2013;69. doi: 10.1038/nrn2038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2038</ArticleId><ArticleId IdType="pubmed">17180163</ArticleId></ArticleIdList></Reference><Reference><Citation>Thome A.D., Harms A.S., Volpicelli-Daley L.A., Standaert D.G. microRNA-155 regulates alpha-synuclein-induced inflammatory responses in models of Parkinson disease. J. Neurosci. 2016;36:2383&#x2013;2390. doi: 10.1523/JNEUROSCI.3900-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3900-15.2016</ArticleId><ArticleId IdType="pmc">PMC4764660</ArticleId><ArticleId IdType="pubmed">26911687</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Lu M., Du R.H., Qiao C., Jiang C.Y., Zhang K.Z., Ding J.H., Hu G. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson&#x2019;s disease. Mol. Neurodegener. 2016;16:11&#x2013;28. doi: 10.1186/s13024-016-0094-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0094-3</ArticleId><ArticleId IdType="pmc">PMC4833896</ArticleId><ArticleId IdType="pubmed">27084336</ArticleId></ArticleIdList></Reference><Reference><Citation>Caggiu E., Paulus K., Mameli G., Arru G., Sechi G.P., Sechi L.A. Differential expression of miRNA 155 and miRNA 146a in Parkinson&#x2019;s disease patients. eNeurologicalSci. 2018;13:1&#x2013;4. doi: 10.1016/j.ensci.2018.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.09.002</ArticleId><ArticleId IdType="pmc">PMC6149197</ArticleId><ArticleId IdType="pubmed">30255159</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao L., Ye Y., Mao H., Lu F., He X., Lu G., Zhang S. MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson&#x2019;s disease. J. Neuroinflamm. 2018;15:13. doi: 10.1186/s12974-018-1053-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1053-4</ArticleId><ArticleId IdType="pmc">PMC5767033</ArticleId><ArticleId IdType="pubmed">29329581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelmus M.M., Nijland P.G., Drukarch B., de Vries H.E., van Horssen J. Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders. Free Radic. Biol. Med. 2012;53:983&#x2013;992. doi: 10.1016/j.freeradbiomed.2012.05.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2012.05.040</ArticleId><ArticleId IdType="pubmed">22687462</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk A.E., Weishaupt J.H., Andersen P.M., Ludolph A.C., Kubisch C. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med. Genet. 2018;30:252&#x2013;258. doi: 10.1007/s11825-018-0185-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11825-018-0185-3</ArticleId><ArticleId IdType="pmc">PMC6132774</ArticleId><ArticleId IdType="pubmed">30220791</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero E.N., Wang H., Mitra J., Hegde P.M., Stowell S.E., Liachko N.F., Kraemer B.C., Garruto R.M., Rao K.S., Hegde M.L. TDP-43/FUS in motor neuron disease: Complexity and challenges. Prog. Neurobiol. 2016;145&#x2013;146:78&#x2013;97. doi: 10.1016/j.pneurobio.2016.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2016.09.004</ArticleId><ArticleId IdType="pmc">PMC5101148</ArticleId><ArticleId IdType="pubmed">27693252</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil V.V., Katzman R.B., Petrucelli L. ALS and FTD: An epigenetic perspective. Acta Neuropathol. 2016;132:487&#x2013;502. doi: 10.1007/s00401-016-1587-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1587-4</ArticleId><ArticleId IdType="pmc">PMC5138862</ArticleId><ArticleId IdType="pubmed">27282474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Bai Z., Qin X., Cheng Y. Aberrations in oxidative stress markers in amyotrophic lateral sclerosis: A systematic review and meta-analysis. Oxid. Med. Cell Longev. 2019;2019:1712323. doi: 10.1155/2019/1712323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/1712323</ArticleId><ArticleId IdType="pmc">PMC6590548</ArticleId><ArticleId IdType="pubmed">31281567</ArticleId></ArticleIdList></Reference><Reference><Citation>Joilin G., Leigh P.N., Newbury S.F., Hafezparast M. An overview of MicroRNAs as biomarkers of ALS. Front. Neurol. 2019;10:186. doi: 10.3389/fneur.2019.00186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00186</ArticleId><ArticleId IdType="pmc">PMC6416171</ArticleId><ArticleId IdType="pubmed">30899244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovanda A., Leonardis L., Zidar J., Koritnik B., Dolenc-Groselj L., Ristic Kovacic S., Curk T., Rogelj B. Differential expression of microRNAs and other small RNAs in muscle tissue of patients with ALS and healthy age-matched controls. Sci. Rep. 2018;8:5609. doi: 10.1038/s41598-018-23139-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-23139-2</ArticleId><ArticleId IdType="pmc">PMC5884852</ArticleId><ArticleId IdType="pubmed">29618798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci C., Marzocchi C., Battistini S. MicroRNAs as biomarkers in amyotrophic lateral sclerosis. Cells. 2018;7:219. doi: 10.3390/cells7110219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells7110219</ArticleId><ArticleId IdType="pmc">PMC6262636</ArticleId><ArticleId IdType="pubmed">30463376</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuti M., Filosa G., Melzi V., Calandriello L., Dioni L., Bollati V., Bresolin N., Comi G.P., Barabino S., Nizzardo M., et al. MicroRNA expression analysis identifies a subset of downregulated miRNAs in ALS motor neuron progenitors. Sci. Rep. 2018;8:10105. doi: 10.1038/s41598-018-28366-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-28366-1</ArticleId><ArticleId IdType="pmc">PMC6031650</ArticleId><ArticleId IdType="pubmed">29973608</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R., Wyles M., Heath P.R., Kazoka M., Wollff H., Shaw P.J., Kirby J. Small RNA sequencing of sporadic amyotrophic lateral sclerosis cerebrospinal fluid reveals differentially expressed miRNAs related to neural and glial activity. Front. Neurosci. 2017;11:731. doi: 10.3389/fnins.2017.00731.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00731</ArticleId><ArticleId IdType="pmc">PMC5767269</ArticleId><ArticleId IdType="pubmed">29375285</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Sun H., Stock R., Blackwood M., Brown R.H., Jr., Mueller C. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci. Transl. Med. 2018;10 doi: 10.1126/scitranslmed.aau6414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6414</ArticleId><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Koval E.D., Shaner C., Zhang P., du Maine X., Fischer K., Tay J., Chau B.N., Wu G.F., Miller T.M. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum. Mol. Genet. 2013;22:4127&#x2013;4135. doi: 10.1093/hmg/ddt261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt261</ArticleId><ArticleId IdType="pmc">PMC3781640</ArticleId><ArticleId IdType="pubmed">23740943</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Wei Q., Gu X., Chen Y., Chen X., Cao B., Ou R., Shang H. Decreased glycogenolysis by miR-338-3p promotes regional glycogen accumulation within the spinal cord of amyotrophic lateral sclerosis mice. Front. Mol. Neurosci. 2019;12:114. doi: 10.3389/fnmol.2019.00114.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00114</ArticleId><ArticleId IdType="pmc">PMC6514045</ArticleId><ArticleId IdType="pubmed">31133799</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakuchi M., Ferlito M., Lowenstein C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. USA. 2008;105:13421&#x2013;13426. doi: 10.1073/pnas.0801613105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0801613105</ArticleId><ArticleId IdType="pmc">PMC2533205</ArticleId><ArticleId IdType="pubmed">18755897</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P., Hanson P.S., Morris C.M. SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson&#x2019;s disease. BMC Neurosci. 2017;18:46. doi: 10.1186/s12868-017-0364-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-017-0364-1</ArticleId><ArticleId IdType="pmc">PMC5455114</ArticleId><ArticleId IdType="pubmed">28578695</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino S., Conte A., Caggiano R., Pierantoni G.M., Faraonio R. Nrf2 pathway in age-related neurological disorders: Insights into MicroRNAs. Cell Physiol. Biochem. 2018;47:1951&#x2013;1976. doi: 10.1159/000491465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000491465</ArticleId><ArticleId IdType="pubmed">29969760</ArticleId></ArticleIdList></Reference><Reference><Citation>Ba Q., Cui C., Wen L., Feng S., Zhou J., Yang K. Schisandrin B shows neuroprotective effect in 6-OHDA-induced Parkinson&#x2019;s disease via inhibiting the negative modulation of miR-34a on Nrf2 pathway. Biomed. Pharmacother. 2015;75:165&#x2013;172. doi: 10.1016/j.biopha.2015.07.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2015.07.034</ArticleId><ArticleId IdType="pubmed">26282218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N., Zhang L., Lu Y., Zhang M., Zhang Z., Wang K., Lv J. Down-regulation of microRNA-142-5p attenuates oxygen-glucose deprivation and reoxygenation-induced neuron injury through up-regulating Nrf2/ARE signaling pathway. Biomed. Pharmacother. 2017;89:1187&#x2013;1195. doi: 10.1016/j.biopha.2017.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.03.011</ArticleId><ArticleId IdType="pubmed">28320085</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschrafi A., Kar A.N., Natera-Naranjo O., MacGibeny M.A., Gioio A.E., Kaplan B.B. MicroRNA-338 regulates the axonal expression of multiple nuclear-encoded mitochondrial mRNAs encoding subunits of the oxidative phosphorylation machinery. Cell Mol. Life Sci. 2012;69:4017&#x2013;4027. doi: 10.1007/s00018-012-1064-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-012-1064-8</ArticleId><ArticleId IdType="pubmed">22773120</ArticleId></ArticleIdList></Reference><Reference><Citation>Shioya M., Obayashi S., Tabunoki H., Arima K., Saito Y., Ishida T., Satoh J. Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol. Appl. Neurobiol. 2010;36:320&#x2013;330. doi: 10.1111/j.1365-2990.2010.01076.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2010.01076.x</ArticleId><ArticleId IdType="pubmed">20202123</ArticleId></ArticleIdList></Reference><Reference><Citation>McColgan P., Tabrizi S.J. Huntington&#x2019;s disease: A clinical review. Eur. J. Neurol. 2018;25:24&#x2013;34. doi: 10.1111/ene.13413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13413</ArticleId><ArticleId IdType="pubmed">28817209</ArticleId></ArticleIdList></Reference><Reference><Citation>Banez-Coronel M., Ayhan F., Tarabochia A.D., Zu T., Perez B.A., Tusi S.K., Pletnikova O., Borchelt D.R., Ross C.A., Margolis R.L., et al. RAN translation in huntington disease. Neuron. 2015;88:667&#x2013;677. doi: 10.1016/j.neuron.2015.10.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.10.038</ArticleId><ArticleId IdType="pmc">PMC4684947</ArticleId><ArticleId IdType="pubmed">26590344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross C.A., Tabrizi S.J. Huntington&#x2019;s disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83&#x2013;98. doi: 10.1016/S1474-4422(10)70245-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70245-3</ArticleId><ArticleId IdType="pubmed">21163446</ArticleId></ArticleIdList></Reference><Reference><Citation>Moumne L., Betuing S., Caboche J. Multiple aspects of gene dysregulation in Huntington&#x2019;s disease. Front. Neurol. 2013;4:127. doi: 10.3389/fneur.2013.00127.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2013.00127</ArticleId><ArticleId IdType="pmc">PMC3806340</ArticleId><ArticleId IdType="pubmed">24167500</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J., Winderickx J., Franssens V., Liu B. A Mitochondria-associated oxidative stress perspective on Huntington&#x2019;s disease. Front. Mol. Neurosci. 2018;11:329. doi: 10.3389/fnmol.2018.00329.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00329</ArticleId><ArticleId IdType="pmc">PMC6156126</ArticleId><ArticleId IdType="pubmed">30283298</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson R., Zuccato C., Belyaev N.D., Guest D.J., Cattaneo E., Buckley N.J. A microRNA-based gene dysregulation pathway in Huntington&#x2019;s disease. Neurobiol. Dis. 2008;29:438&#x2013;445. doi: 10.1016/j.nbd.2007.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2007.11.001</ArticleId><ArticleId IdType="pubmed">18082412</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer A.N., Xing Y., Harper S.Q., Jones L., Davidson B.L. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington&#x2019;s disease. J. Neurosci. 2008;28:14341&#x2013;14346. doi: 10.1523/JNEUROSCI.2390-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2390-08.2008</ArticleId><ArticleId IdType="pmc">PMC3124002</ArticleId><ArticleId IdType="pubmed">19118166</ArticleId></ArticleIdList></Reference><Reference><Citation>Savas J.N., Makusky A., Ottosen S., Baillat D., Then F., Krainc D., Shiekhattar R., Markey S.P., Tanese N. Huntington&#x2019;s disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc. Natl. Acad. Sci. USA. 2008;105:10820&#x2013;10825. doi: 10.1073/pnas.0800658105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0800658105</ArticleId><ArticleId IdType="pmc">PMC2504805</ArticleId><ArticleId IdType="pubmed">18669659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pircs K., Petri R., Madsen S., Brattas P.L., Vuono R., Ottosson D.R., St-Amour I., Hersbach B.A., Matusiak-Bruckner M., Lundh S.H., et al. Huntingtin aggregation impairs autophagy, leading to argonaute-2 accumulation and global MicroRNA dysregulation. Cell Rep. 2018;24:1397&#x2013;1406. doi: 10.1016/j.celrep.2018.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.07.017</ArticleId><ArticleId IdType="pubmed">30089251</ArticleId></ArticleIdList></Reference><Reference><Citation>Banez-Coronel M., Porta S., Kagerbauer B., Mateu-Huertas E., Pantano L., Ferrer I., Guzman M., Estivill X., Marti E. A pathogenic mechanism in Huntington&#x2019;s disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet. 2012;8:e1002481. doi: 10.1371/journal.pgen.1002481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002481</ArticleId><ArticleId IdType="pmc">PMC3285580</ArticleId><ArticleId IdType="pubmed">22383888</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.T., Chu K., Im W.S., Yoon H.J., Im J.Y., Park J.E., Park K.H., Jung K.H., Lee S.K., Kim M., et al. Altered microRNA regulation in Huntington&#x2019;s disease models. Exp. Neurol. 2011;227:172&#x2013;179. doi: 10.1016/j.expneurol.2010.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.10.012</ArticleId><ArticleId IdType="pubmed">21035445</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti E., Pantano L., Banez-Coronel M., Llorens F., Minones-Moyano E., Porta S., Sumoy L., Ferrer I., Estivill X. A myriad of miRNA variants in control and Huntington&#x2019;s disease brain regions detected by massively parallel sequencing. Nucleic Acids Res. 2010;38:7219&#x2013;7235. doi: 10.1093/nar/gkq575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq575</ArticleId><ArticleId IdType="pmc">PMC2978354</ArticleId><ArticleId IdType="pubmed">20591823</ArticleId></ArticleIdList></Reference><Reference><Citation>Wexler N.S., Lorimer J., Porter J., Gomez F., Moskowitz C., Shackell E., Marder K., Penchaszadeh G., Roberts S.A., Gayan J., et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington&#x2019;s disease age of onset. Proc. Natl. Acad. Sci. USA. 2004;101:3498&#x2013;3503. doi: 10.1073/pnas.0308679101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0308679101</ArticleId><ArticleId IdType="pmc">PMC373491</ArticleId><ArticleId IdType="pubmed">14993615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblatt A., Liang K.Y., Zhou H., Abbott M.H., Gourley L.M., Margolis R.L., Brandt J., Ross C.A. The association of CAG repeat length with clinical progression in Huntington disease. Neurology. 2006;66:1016&#x2013;1020. doi: 10.1212/01.wnl.0000204230.16619.d9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000204230.16619.d9</ArticleId><ArticleId IdType="pubmed">16606912</ArticleId></ArticleIdList></Reference><Reference><Citation>Johri A., Beal M.F. Antioxidants in Huntington&#x2019;s disease. Biochim. Biophys. Acta. 2012;1822:664&#x2013;674. doi: 10.1016/j.bbadis.2011.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2011.11.014</ArticleId><ArticleId IdType="pmc">PMC3303936</ArticleId><ArticleId IdType="pubmed">22138129</ArticleId></ArticleIdList></Reference><Reference><Citation>Duran R., Barrero F.J., Morales B., Luna J.D., Ramirez M., Vives F. Oxidative stress and plasma aminopeptidase activity in Huntington&#x2019;s disease. J. Neural. Transm. 2010;117:325&#x2013;332. doi: 10.1007/s00702-009-0364-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-009-0364-0</ArticleId><ArticleId IdType="pubmed">20094738</ArticleId></ArticleIdList></Reference><Reference><Citation>Olejniczak M., Kotowska-Zimmer A., Krzyzosiak W. Stress-induced changes in miRNA biogenesis and functioning. Cell Mol. Life Sci. 2018;75:177&#x2013;191. doi: 10.1007/s00018-017-2591-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-017-2591-0</ArticleId><ArticleId IdType="pmc">PMC5756259</ArticleId><ArticleId IdType="pubmed">28717872</ArticleId></ArticleIdList></Reference><Reference><Citation>Asada S., Takahashi T., Isodono K., Adachi A., Imoto H., Ogata T., Ueyama T., Matsubara H., Oh H. Downregulation of Dicer expression by serum withdrawal sensitizes human endothelial cells to apoptosis. Am. J. Physiol. Heart Circ. Physiol. 2008;295:H2512&#x2013;H2521. doi: 10.1152/ajpheart.00233.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00233.2008</ArticleId><ArticleId IdType="pubmed">18978195</ArticleId></ArticleIdList></Reference><Reference><Citation>Inukai S., de Lencastre A., Turner M., Slack F. Novel microRNAs differentially expressed during aging in the mouse brain. PLoS ONE. 2012;7:e40028. doi: 10.1371/journal.pone.0040028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0040028</ArticleId><ArticleId IdType="pmc">PMC3402511</ArticleId><ArticleId IdType="pubmed">22844398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig N., Leidinger P., Becker K., Backes C., Fehlmann T., Pallasch C., Rheinheimer S., Meder B., Stahler C., Meese E., et al. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016;44:3865&#x2013;3877. doi: 10.1093/nar/gkw116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw116</ArticleId><ArticleId IdType="pmc">PMC4856985</ArticleId><ArticleId IdType="pubmed">26921406</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal V., Bell G.W., Nam J.W., Bartel D.P. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4 doi: 10.7554/eLife.05005.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.05005</ArticleId><ArticleId IdType="pmc">PMC4532895</ArticleId><ArticleId IdType="pubmed">26267216</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkos T.M., Koscianska E., Krzyzosiak W.J. Practical aspects of microRNA target prediction. Curr. Mol. Med. 2011;11:93&#x2013;109. doi: 10.2174/156652411794859250.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652411794859250</ArticleId><ArticleId IdType="pmc">PMC3182075</ArticleId><ArticleId IdType="pubmed">21342132</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H.Y., Gonzalez-Martin A., Miletic A.V., Lai M., Knight S., Sabouri-Ghomi M., Head S.R., Macauley M.S., Rickert R.C., Xiao C. Transfection of microRNA mimics should be used with caution. Front. Genet. 2015;6:340. doi: 10.3389/fgene.2015.00340.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2015.00340</ArticleId><ArticleId IdType="pmc">PMC4667072</ArticleId><ArticleId IdType="pubmed">26697058</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A., Roshan R., Moisoi N., Pradervand S., Moser R., Pillai B., Luthi-Carter R. Comprehensive expression analyses of neural cell-type-specific miRNAs identify new determinants of the specification and maintenance of neuronal phenotypes. J. Neurosci. 2013;33:5127&#x2013;5137. doi: 10.1523/JNEUROSCI.0600-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0600-12.2013</ArticleId><ArticleId IdType="pmc">PMC6705001</ArticleId><ArticleId IdType="pubmed">23516279</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam J.W., Rissland O.S., Koppstein D., Abreu-Goodger C., Jan C.H., Agarwal V., Yildirim M.A., Rodriguez A., Bartel D.P. Global analyses of the effect of different cellular contexts on microRNA targeting. Mol. Cell. 2014;53:1031&#x2013;1043. doi: 10.1016/j.molcel.2014.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2014.02.013</ArticleId><ArticleId IdType="pmc">PMC4062300</ArticleId><ArticleId IdType="pubmed">24631284</ArticleId></ArticleIdList></Reference><Reference><Citation>He M., Liu Y., Wang X., Zhang M.Q., Hannon G.J., Huang Z.J. Cell-type-based analysis of microRNA profiles in the mouse brain. Neuron. 2012;73:35&#x2013;48. doi: 10.1016/j.neuron.2011.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.010</ArticleId><ArticleId IdType="pmc">PMC3270494</ArticleId><ArticleId IdType="pubmed">22243745</ArticleId></ArticleIdList></Reference><Reference><Citation>Svoboda P. A toolbox for miRNA analysis. FEBS Lett. 2015;589:1694&#x2013;1701. doi: 10.1016/j.febslet.2015.04.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2015.04.054</ArticleId><ArticleId IdType="pubmed">25957774</ArticleId></ArticleIdList></Reference><Reference><Citation>Knauss J.L., Bian S., Sun T. Plasmid-based target protectors allow specific blockade of miRNA silencing activity in mammalian developmental systems. Front. Cell Neurosci. 2013;7:163. doi: 10.3389/fncel.2013.00163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00163</ArticleId><ArticleId IdType="pmc">PMC3781311</ArticleId><ArticleId IdType="pubmed">24068984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran F.A., Hsu P.D., Wright J., Agarwala V., Scott D.A., Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 2013;8:2281&#x2013;2308. doi: 10.1038/nprot.2013.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.143</ArticleId><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816&#x2013;821. doi: 10.1126/science.1225829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1225829</ArticleId><ArticleId IdType="pmc">PMC6286148</ArticleId><ArticleId IdType="pubmed">22745249</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasiunas G., Barrangou R., Horvath P., Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl. Acad. Sci. USA. 2012;109:E2579&#x2013;E2586. doi: 10.1073/pnas.1208507109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1208507109</ArticleId><ArticleId IdType="pmc">PMC3465414</ArticleId><ArticleId IdType="pubmed">22949671</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin N.D., Bai G., Klug J.R., Bonanomi D., Pankratz M.T., Gifford W.D., Hinckley C.A., Sternfeld M.J., Driscoll S.P., Dominguez B., et al. Loss of motoneuron-specific microRNA-218 causes systemic neuromuscular failure. Science. 2015;350:1525&#x2013;1529. doi: 10.1126/science.aad2509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad2509</ArticleId><ArticleId IdType="pmc">PMC4913787</ArticleId><ArticleId IdType="pubmed">26680198</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H., Yi B., Ma R., Zhang X., Zhao H., Xi Y. CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. Sci. Rep. 2016;6:22312. doi: 10.1038/srep22312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep22312</ArticleId><ArticleId IdType="pmc">PMC4770416</ArticleId><ArticleId IdType="pubmed">26924382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurata J.S., Lin R.J. MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs. RNA. 2018;24:966&#x2013;981. doi: 10.1261/rna.066282.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.066282.118</ArticleId><ArticleId IdType="pmc">PMC6004052</ArticleId><ArticleId IdType="pubmed">29720387</ArticleId></ArticleIdList></Reference><Reference><Citation>Back S., Necarsulmer J., Whitaker L.R., Coke L.M., Koivula P., Heathward E.J., Fortuno L.V., Zhang Y., Yeh C.G., Baldwin H.A., et al. Neuron-specific genome modification in the adult rat brain using CRISPR-Cas9 transgenic rats. Neuron. 2019;102:105&#x2013;119. doi: 10.1016/j.neuron.2019.01.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.035</ArticleId><ArticleId IdType="pubmed">30792150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess G.T., Tycko J., Yao D., Bassik M.C. Methods and applications of CRISPR-mediated base editing in eukaryotic genomes. Mol. Cell. 2017;68:26&#x2013;43. doi: 10.1016/j.molcel.2017.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.09.029</ArticleId><ArticleId IdType="pmc">PMC5997582</ArticleId><ArticleId IdType="pubmed">28985508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafra M.P., Schatoff E.M., Katti A., Foronda M., Breinig M., Schweitzer A.Y., Simon A., Han T., Goswami S., Montgomery E., et al. Optimized base editors enable efficient editing in cells, organoids and mice. Nat. Biotechnol. 2018;36:888&#x2013;893. doi: 10.1038/nbt.4194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4194</ArticleId><ArticleId IdType="pmc">PMC6130889</ArticleId><ArticleId IdType="pubmed">29969439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J.H., Miller S.M., Geurts M.H., Tang W., Chen L., Sun N., Zeina C.M., Gao X., Rees H.A., Lin Z., et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. 2018;556:57&#x2013;63. doi: 10.1038/nature26155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature26155</ArticleId><ArticleId IdType="pmc">PMC5951633</ArticleId><ArticleId IdType="pubmed">29512652</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzalone A.V., Randolph P.B., Davis J.R., Sousa A.A., Koblan L.W., Levy J.M., Chen P.J., Wilson C., Newby G.A., Raguram A., et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019 doi: 10.1038/s41586-019-1711-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1711-4</ArticleId><ArticleId IdType="pmc">PMC6907074</ArticleId><ArticleId IdType="pubmed">31634902</ArticleId></ArticleIdList></Reference><Reference><Citation>Domanskyi A., Saarma M., Airavaara M. Prospects of neurotrophic factors for Parkinson&#x2019;s disease: Comparison of protein and gene therapy. Hum. Gene Ther. 2015;26:550&#x2013;559. doi: 10.1089/hum.2015.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2015.065</ArticleId><ArticleId IdType="pubmed">26176331</ArticleId></ArticleIdList></Reference><Reference><Citation>Espay A.J., Brundin P., Lang A.E. Precision medicine for disease modification in Parkinson disease. Nat. Rev. Neurol. 2017;13:119&#x2013;126. doi: 10.1038/nrneurol.2016.196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.196</ArticleId><ArticleId IdType="pubmed">28106064</ArticleId></ArticleIdList></Reference><Reference><Citation>La Manno G., Gyllborg D., Codeluppi S., Nishimura K., Salto C., Zeisel A., Borm L.E., Stott S.R.W., Toledo E.M., Villaescusa J.C., et al. Molecular diversity of midbrain development in mouse, human, and stem cells. Cell. 2016;167:566&#x2013;580. doi: 10.1016/j.cell.2016.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.09.027</ArticleId><ArticleId IdType="pmc">PMC5055122</ArticleId><ArticleId IdType="pubmed">27716510</ArticleId></ArticleIdList></Reference><Reference><Citation>Creed R.B., Goldberg M.S. New developments in genetic rat models of Parkinson&#x2019;s disease. Mov. Disord. 2018;33:717&#x2013;729. doi: 10.1002/mds.27296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27296</ArticleId><ArticleId IdType="pmc">PMC5992003</ArticleId><ArticleId IdType="pubmed">29418019</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesselet M.F., Richter F. Modelling of Parkinson&#x2019;s disease in mice. Lancet Neurol. 2011;10:1108&#x2013;1118. doi: 10.1016/S1474-4422(11)70227-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70227-7</ArticleId><ArticleId IdType="pubmed">22094131</ArticleId></ArticleIdList></Reference><Reference><Citation>Blesa J., Przedborski S. Parkinson&#x2019;s disease: Animal models and dopaminergic cell vulnerability. Front. Neuroanat. 2014;8:155. doi: 10.3389/fnana.2014.00155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2014.00155</ArticleId><ArticleId IdType="pmc">PMC4266040</ArticleId><ArticleId IdType="pubmed">25565980</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezikov E., Thuemmler F., van Laake L.W., Kondova I., Bontrop R., Cuppen E., Plasterk R.H. Diversity of microRNAs in human and chimpanzee brain. Nat. Genet. 2006;38:1375&#x2013;1377. doi: 10.1038/ng1914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1914</ArticleId><ArticleId IdType="pubmed">17072315</ArticleId></ArticleIdList></Reference><Reference><Citation>Londin E., Loher P., Telonis A.G., Quann K., Clark P., Jing Y., Hatzimichael E., Kirino Y., Honda S., Lally M., et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc. Natl. Acad. Sci. USA. 2015;112:E1106&#x2013;E1115. doi: 10.1073/pnas.1420955112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1420955112</ArticleId><ArticleId IdType="pmc">PMC4364231</ArticleId><ArticleId IdType="pubmed">25713380</ArticleId></ArticleIdList></Reference><Reference><Citation>McLoughlin H.S., Wan J., Spengler R.M., Xing Y., Davidson B.L. Human-specific microRNA regulation of FOXO1: Implications for microRNA recognition element evolution. Hum. Mol. Genet. 2014;23:2593&#x2013;2603. doi: 10.1093/hmg/ddt655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt655</ArticleId><ArticleId IdType="pubmed">24368418</ArticleId></ArticleIdList></Reference><Reference><Citation>Franca G.S., Hinske L.C., Galante P.A., Vibranovski M.D. Unveiling the impact of the genomic architecture on the evolution of vertebrate microRNAs. Front. Genet. 2017;8:34. doi: 10.3389/fgene.2017.00034.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2017.00034</ArticleId><ArticleId IdType="pmc">PMC5359303</ArticleId><ArticleId IdType="pubmed">28377786</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N., Zheng J., Chen Z., Liu Y., Dura B., Kwak M., Xavier-Ferrucio J., Lu Y.C., Zhang M., Roden C., et al. Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation. Nat. Commun. 2019;10:95. doi: 10.1038/s41467-018-07981-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07981-6</ArticleId><ArticleId IdType="pmc">PMC6327095</ArticleId><ArticleId IdType="pubmed">30626865</ArticleId></ArticleIdList></Reference><Reference><Citation>Engle S.J., Blaha L., Kleiman R.J. Best practices for translational disease modeling using human iPSC-derived neurons. Neuron. 2018;100:783&#x2013;797. doi: 10.1016/j.neuron.2018.10.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.10.033</ArticleId><ArticleId IdType="pubmed">30465765</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa E., Botta-Orfila T., Morato X., Calatayud C., Ferrer-Lorente R., Marti M.J., Fernandez M., Gaig C., Raya A., Consiglio A., et al. MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients. Neurobiol. Aging. 2018;69:283&#x2013;291. doi: 10.1016/j.neurobiolaging.2018.05.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.05.032</ArticleId><ArticleId IdType="pubmed">29935433</ArticleId></ArticleIdList></Reference><Reference><Citation>Katerji M., Filippova M., Duerksen-Hughes P. Approaches and methods to measure oxidative stress in clinical samples: Research applications in the cancer field. Oxid. Med. Cell Longev. 2019;2019:1279250. doi: 10.1155/2019/1279250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/1279250</ArticleId><ArticleId IdType="pmc">PMC6434272</ArticleId><ArticleId IdType="pubmed">30992736</ArticleId></ArticleIdList></Reference><Reference><Citation>Grenier K., Kao J., Diamandis P. Three-dimensional modeling of human neurodegeneration: Brain organoids coming of age. Mol. Psychiatry. 2019 doi: 10.1038/s41380-019-0500-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0500-7</ArticleId><ArticleId IdType="pubmed">31444473</ArticleId></ArticleIdList></Reference><Reference><Citation>Windrem M.S., Schanz S.J., Morrow C., Munir J., Chandler-Militello D., Wang S., Goldman S.A. A competitive advantage by neonatally engrafted human glial progenitors yields mice whose brains are chimeric for human glia. J. Neurosci. 2014;34:16153&#x2013;16161. doi: 10.1523/JNEUROSCI.1510-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1510-14.2014</ArticleId><ArticleId IdType="pmc">PMC4244478</ArticleId><ArticleId IdType="pubmed">25429155</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso T., Adler A.F., Mattsson B., Hoban D.B., Nolbrant S., Wahlestedt J.N., Kirkeby A., Grealish S., Bjorklund A., Parmar M. Target-specific forebrain projections and appropriate synaptic inputs of hESC-derived dopamine neurons grafted to the midbrain of parkinsonian rats. J. Comp. Neurol. 2018;526:2133&#x2013;2146. doi: 10.1002/cne.24500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.24500</ArticleId><ArticleId IdType="pmc">PMC6175216</ArticleId><ArticleId IdType="pubmed">30007046</ArticleId></ArticleIdList></Reference><Reference><Citation>Grealish S., Diguet E., Kirkeby A., Mattsson B., Heuer A., Bramoulle Y., Van Camp N., Perrier A.L., Hantraye P., Bjorklund A., et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson&#x2019;s disease. Cell Stem Cell. 2014;15:653&#x2013;665. doi: 10.1016/j.stem.2014.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2014.09.017</ArticleId><ArticleId IdType="pmc">PMC4232736</ArticleId><ArticleId IdType="pubmed">25517469</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler A.F., Cardoso T., Nolbrant S., Mattsson B., Hoban D.B., Jarl U., Wahlestedt J.N., Grealish S., Bjorklund A., Parmar M. HESC-derived dopaminergic transplants integrate into basal ganglia circuitry in a preclinical model of Parkinson&#x2019;s disease. Cell Rep. 2019;28:3462&#x2013;3473. doi: 10.1016/j.celrep.2019.08.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.08.058</ArticleId><ArticleId IdType="pmc">PMC6899556</ArticleId><ArticleId IdType="pubmed">31553914</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>